News & Publications


Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

Prous Institute Presents Its Progress in Cardiotoxicity Modeling at the SOT 2011

Washington D.C., USA: Prous Institute for Biomedical Research will be jointly presenting a scientific poster with the US FDA Center for Drug Evaluation and Research (CDER) at the Annual Meeting of the Society of Toxicology in Washington D.C.. The poster is titled: “Computational Modeling for QT Prolongation: A Drug Cardiovascular Safety Endpoint of Paramount Importance”. The poster will present one of the new modeling efforts with BioEpisteme® v.4.1, a quantitative structure-activity relationship (QSAR) software program that creates customized drug prediction models against fundamental research endpoints.  BioEpisteme® was made available to FDA/CDER/OPS via an agency approved Research Collaboration Agreement with Prous Institute. The poster will form part of the SOT poster session: “Bioinformatic Profiling and Computational Pathway Prediction” which will take place on March 7, 2011 from 9:30 am to 12:30 pm in the Exhibit Hall (Convention Center), Abstract Number: 146, Poster Board number: 235.


“Due of the potentially catastrophic nature of unanticipated “off-target” drug-related cardiovascular effects, adequate assessment of cardiac safety is of paramount importance.  Torsades de pointes (TdP), which is a potentially lethal cardiac arrhythmia, has been linked with a number of drugs after they were approved and made available for purchase.  Early prediction would have allowed for a more thorough assessment of clinical trial data, potentially halted the clinical trials or terminated the drug's development. QT interval prolongation is a precursor to TdP, and therefore its early detection would allow for better clinical development of potential drug products. The measurement of QTc interval effects has been adopted into the FDA’s and international health authority guidelines as a method of assessing the pro-arrhythmic potential of new drugs.  In recognizing this public health concern and the goal of developing better predictive methods, Prous Institute has deployed a computational modeling approach based on new, high quality, human clinical trial data. This data will support the development of innovative qualitative and quantitative structure-activity models that can make predictions based on chemical structure. This present effort is innovative, where human clinical trial data will be used to construct predictive computational toxicology models to help screen drugs, and will serve as a support tool for risk assessment of new drugs.” 

To learn more about of BioEpisteme® prediction software, please visit

Related Articles

New Research Collaboration Agreement (RCA) between Prous Institute and the FDA-CFSAN (Center for Food Safety and Applied Nutrition) Washington D.C., USA: The Food and Drug Administration's Center for Food Safety and Applied Nutrition(FDA/CFSAN) and Prous Institute for Biomedical Re...
SOT 2011: “In Silico Predictive Model for Drug-Induced Phospholipidosis using BioEpisteme software" Washington D.C., USA: Prous Institute’s BioEpisteme® software will be featured in a scientific poster to be presented by the US FDA Center f...
Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities.&nbs...
Prediction of Drug-Related Cardiac Adverse Effects in Humans--A: Creation of a Database of Effects and Identification of Factors Affecting their Occurrence. Authors: Matthews EJ, Frid AA. Journal: Regul Toxicol Pharmacol. 2010 Apr;56(3):247-75., PMID: 19932726 Link to Article
Toxicological and Clinical Computational Analysis by the Informatics and Computational Safety Analysis Staff of the US FDA/CDER Authors:  Daniel R. Benz, Edwin J. Matthews, Naomi L. Kruhlak, Anna A. Frid, Barbara L. Minnier and Joseph F. Contrera.  Meeting: AATEX 1...